Adverse events in second- and third-line treatments for acute and chronic graft-versus-host disease: systematic review.

ABSTRACT:

Background

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with an increased risk of graft-versus-host disease (GvHD), a strong prognostic predictor of early mortality within the first 2 years following allo-HSCT. The objective of this study was to describe the harm outcomes reported among patients receiving second- and third-line treatment as part of the management for GvHD via a systematic literature review.

Methods

A total of 34 studies met the systematic review inclusion criteria, reporting adverse events (AEs) across 12 different second- and third-line therapies.

Results

A total of 14 studies reported AEs across nine different therapies used in the treatment of acute GvHD (aGvHD), 17 studies reported AEs of eight differe

SUBMITTER: Velickovic VM 

PROVIDER: S-EPMC7727084 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature